Investigating the effect of lavender on depression in patients with multiple sclerosis

Comparison of the effectiveness of lavender capsules (linazepam) with placebo in improving depression symptoms in patients with multiple sclerosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190726044339N4

Enrollment

Registered

2023-03-03

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis.

Interventions

Intervention 1: Intervention Group: Participants in this group will be prescribed one capsule of linazepam, which contains lavender essence, one hour before bedtime for eight weeks at night. This lina

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Men and women with Relapsing-remitting multiple sclerosis patients with aged between ??-?? years Score above ?? according to Persian- version of the Beck Depression Inventory-II (BDI-II-Persian)

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding Allergy to lavender Unstable heart, kidney and liver patients Seizures Hypothyroidism Consumption of alcohol or drugs Patients who do not follow the study completely Patients with severe depression

Design outcomes

Primary

Measure	Time frame
Change in Beck questionnaire score. Timepoint: Measurement of depression severity at the beginning of the study (before the start of the intervention) and 4, 8 weeks after the start of taking the drug or placebo. Method of measurement: Depression Beck questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Dehbozorgi

Shiraz University of Medical Sciences

dehbozorgis@sums.ac.ir+98 71 3228 7237

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026